Evozyne: Funding, Investors & Team (Sep 2026)
Evozyne, headquartered in Chicago, Illinois, is a generative AI company that has a strong focus on therapeutic discovery and drug development. Specializing in protein design and molecular scale, the company's main objective is to revolutionize protein design in order to unleash the power of innovative proteins, effectively addressing intricate human and societal problems. Founded in 2020, Evozyne operates in the biotechnology sector.
Evozyne has raised $81.0M across 1 funding round on record, the most recent a Series B of $81.0M announced in Sep 2023.
That round is above the $5.7M median round size for Artificial Intelligence companies tracked on FundedIQ over the last two years.
Evozyne Company Profile and Key Stats
Latest funding round on record: Sep 2023.
Evozyne Funding Rounds
Evozyne Founders and Leadership Team
No contact details are on record for this team yet.
Evozyne Funding Compared to Other Artificial Intelligence Startups
Evozyne's latest round of $81.0M is above the median round in Artificial Intelligence. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Evozyne in Artificial Intelligence and Chicago
Companies Similar to Evozyne
Cradlewise is an intelligent baby crib that learns from the baby's sleep patterns, spots the first signs of…
Capacity is an AI-powered helpdesk that automates support for customers and employees. Capacity connects…
AfterQuery is an artificial intelligence research and data platform focused on creating high-quality,…
The future of translation is conversational and Language I/O’s proprietary machine translation optimization…
Greptile is a platform driven by artificial intelligence that evaluates codebases and improves development…
Rhealth is a biotechnology company offering hospitals health management solutions utilizing advanced AI…
Socure is a predictive analytics platform for digital identity verification of consumers. Socure's predictive…
Instinct is an artificial intelligence startup developing AI technology.
Significant gives vehicle-mounted PC vision innovation that distinguishes visual deformities in network…
Cloverleaf AI exists to help you fill your pipeline with high-quality SLED leads. Tell us what you deliver,…
Emerald AI develops software and platforms that manage and coordinate energy use for artificial intelligence…
Evozyne Funding FAQs
What does Evozyne do?
Evozyne, headquartered in Chicago, Illinois, is a generative AI company that has a strong focus on therapeutic discovery and drug development. Specializing in protein design and molecular scale, the company's main objective is to revolutionize protein design in order to unleash the power of innovative proteins, effectively addressing intricate human and societal problems. Founded in 2020, Evozyne operates in the biotechnology sector.
How much funding has Evozyne raised?
Evozyne has raised $81.0M across 1 round on record. The most recent is a Series B of $81.0M announced in Sep 2023.
When did Evozyne last raise funding?
Evozyne's most recent funding round on record is a Series B of $81.0M, announced in Sep 2023.
Who founded Evozyne?
FundedIQ lists Andrew Ferguson (Founder) at Evozyne.
Where is Evozyne headquartered?
Evozyne is based in Chicago, Illinois, United States.
How many employees does Evozyne have?
Evozyne is in the 101-250 employee band.
How does Evozyne's funding compare to other Artificial Intelligence startups?
Evozyne's latest round of $81.0M is above the $5.7M median round size for Artificial Intelligence companies on FundedIQ across 7,234 tracked companies over the last two years.
About FundedIQ's Evozyne Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Evozyne is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.